Kalypsys recognizes the value and importance of working in a collaborative partnership that utilizes epiK™.
We encourage you to explore the possibilities.
Discovery Partnerships
epiK™ and Saturation Discovery are ideally suited to the discovery and development of next generation medicines. epiK™ has the flexibility to be directed towards any target or therapeutic area. We value the opportunity to build a franchise partnership with your organization in any given therapeutic area.
Product Partnerships
Kalypsys is interested in a partnership to advance the following compounds to late stage trials and commercialization:
KD7040
Topically administered iNOS inhibitor exiting a Phase IIa trial in post-herpetic neuralgia.
KD7332
Orally administered iNOS inhibitor poised for IND filing that has shown efficacy in a wide range of pain and inflammation models.
KD3010
Orally administered PPAR δ -selective agonist which has shown preclinical potential in models of diabetes and dyslipidemia, and is poised to enter Phase II. PPAR δ -selective agonists are currently being evaluated in preclinical models of nonalcoholic steatohepatitis (NASH) and diabetic wound healing. Phase I Clinical Trial Data Poster
Please visit our Partnering page for additional information or contact Daniel Ripley, Senior Director of Business Development at dripley@kalypsys.com to discuss opportunities in this space.
Kalypsys Systems
Kalypsys offers our proprietary technology and informatics solutions through our Kalypsys Systems business unit. This suite of products provides an avenue for increased productivity and reliability that is unmatched in the area of automated drug discovery.
FOR MORE INFORMATION CONTACT:
Discovery and Product Partnerships
Daniel Ripley
Sr. Director of Business Development
+1 (858) 754-3460
dripley@kalypsys.com
Systems Sales
Paul Queeney
Associate Director of Systems Engineering
+1 (858) 754-3376
pqueeney@kalypsys.com
